Section of Vascular Surgery, Department of Surgery, Washington University in St. Louis, St. Louis, Mo.
Division of Cardiothoracic Surgery, Department of Surgery, Washington University in St. Louis, St. Louis, Mo.
J Vasc Surg. 2014 Jun;59(6):1622-7. doi: 10.1016/j.jvs.2013.12.014. Epub 2014 Jan 18.
To assess the effect of extremity vascular complications (EVCs, including ischemia or vessel trauma) on the outcomes of patients receiving cardiac support devices (CSDs, including ventricular assist device [VAD] and extracorporeal membrane oxygenation [ECMO]).
Institutional Review Board-approved, retrospective review of a prospectively maintained database of all temporary and permanent CSD recipients from 7/1/10 to 6/30/12. Patient demographics, procedural data, and outcomes were analyzed. The primary endpoint was all-cause mortality at 30-days post-CSD initiation.
Of 208 patients who received CSDs, 31 (14.9%) experienced EVC: 13 (8.9%) of the 146 permanent VADs, 10 (26.3%) of the 38 temporary VADs, and 8 (33.3%) of the 24 ECMO patients. The 30-day mortality for CSD-EVC patients was not significantly higher than that of the CSD patients who did not experience EVC for permanent VAD (15.4% vs 4.5%; P = .15) and ECMO patients (50.0% vs 68.75%; P = 1.00), but was significantly higher for temporary VAD patients (80.0% vs 35.7%; P = .03). Within the CSD-EVC cohort, patients who received a temporary VAD had a significantly higher 30-day mortality and decision to withdraw care after EVC compared with those who received a permanent VAD (P = .01 and P < .01, respectively). Looking beyond the 30-day window, EVC was associated with higher mortality rates in the permanent VAD population (53.8% vs 25.6%; P = .025) but not the temporary VAD or ECMO groups.
In temporary VAD recipients, EVCs result in higher 30-day mortality, more frequent withdrawal of care, and shortened survival time relative to the global temporary VAD group. EVC in permanent VAD recipients did not affect early (30-day) mortality rates, but strongly predicted a higher cumulative mortality risk for the 2-year study period. Overall ECMO mortality rates were high, and not significantly impacted by the occurrence of EVC. The nature of the EVC (cannulation site complication vs embolic injury) did not impact mortality. This data provides quality improvement targets for VAD programs.
评估肢体血管并发症(EVC,包括缺血或血管损伤)对接受心脏支持设备(CSD,包括心室辅助装置[VAD]和体外膜氧合[ECMO])的患者结局的影响。
对 2010 年 7 月 1 日至 2012 年 6 月 30 日期间所有接受临时和永久性 CSD 的患者的前瞻性维护数据库进行机构审查委员会批准的回顾性审查。分析患者人口统计学、程序数据和结局。主要终点是 CSD 启动后 30 天的全因死亡率。
在接受 CSD 的 208 名患者中,有 31 名(14.9%)发生 EVC:146 名永久性 VAD 中有 13 名(8.9%),38 名临时 VAD 中有 10 名(26.3%),24 名 ECMO 患者中有 8 名(33.3%)。CSD-EVC 患者的 30 天死亡率与未发生 EVC 的永久性 VAD(15.4%比 4.5%;P=0.15)和 ECMO 患者(50.0%比 68.75%;P=1.00)相比没有显著更高,但临时 VAD 患者的死亡率显著更高(80.0%比 35.7%;P=0.03)。在 CSD-EVC 队列中,接受临时 VAD 的患者与接受永久性 VAD 的患者相比,EVC 后 30 天死亡率和决定停止治疗的比例明显更高(P=0.01 和 P<0.01)。放眼 30 天以外,EVC 与永久性 VAD 人群的死亡率升高相关(53.8%比 25.6%;P=0.025),但与临时 VAD 或 ECMO 组无关。
在临时 VAD 接受者中,EVC 导致 30 天死亡率更高、更频繁地停止治疗以及相对于全球临时 VAD 组生存时间缩短。EVC 对永久性 VAD 接受者的早期(30 天)死亡率没有影响,但强烈预示着 2 年研究期间更高的累积死亡率风险。总体 ECMO 死亡率较高,EVC 的发生并未显著影响。EVC 的性质(插管部位并发症与栓塞性损伤)并未影响死亡率。该数据为 VAD 计划提供了质量改进目标。